- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
UK's NICE Wins Drug Price War With GSK
Although approved last September in the European Union, the National Institute for Health and Care Excellence had refused to cover the drug at the company-dictated price, which resulted in patients paying out-of-pocket.
A skin cancer drug developed by GlaxoSmithKline will be available through the United Kingdom's National Health Service after the company agreed to a secret discount.
Tafinlar, which fights melanoma, has won the green light from the National Institute for Health and Care Excellence (NICE), provided GSK supplies it at an undisclosed discount to the £1,400-per-week list price.
The drug has been approved for use in the European Union since September 2013, but once it has received final NICE approval, patients will not need to pay out of pocket to use it.
NICE said it had fast-tracked its recommendation for Tafinlar to the final draft stage in order to accelerate access to the treatment.
Link to the article: http://bit.ly/1p2mXwy
Source: The Telegraph
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy
December 16th 2025The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.
Read More
